We are pleased to confirm the execution of a co-marketing agreement with US contract research organisation Spanios LLC.

This marks Inaphaea's first co-marketing agreement in the US, providing our high-throughput drug screening services with patient-derived cells (PDCs) as an initial step before transitioning to Spanios's proprietary patient-derived tumoroids (PDTs).

Dr Mark Eccleston, Director of Inaphaea BioLabs and CEO of ValiRx plc comments: "We are excited to be working with a highly innovative partner like Spanios. Bringing therapies to market faster requires better models for screening drugs to deliver more accurate and translatable results. Inaphaea has focussed on the early stage of this process where, typically, larger numbers of candidates need to be refined for screening in disease relevant models. We can then pass on the best candidates to Spanios for testing in their organoid platform."

Read more about the agreement here.